ReviewExpert opinion on investigational drugs2013

Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Alice C Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.